Google Doubles Down on Spending as AI Fear Returns | Prof G Markets
TL;DR
Google's plan to nearly double capital expenditures to $180 billion reignited market fears over AI infrastructure costs, while software stocks cratered on existential business model concerns and the GLP-1 weight-loss market saw Eli Lilly surge as rival Novo Nordisk collapsed.
💰 Google's Massive AI Infrastructure Bet 3 insights
Record $400 billion annual revenue and 48% cloud growth
Google reported its first-ever $400 billion revenue year with cloud revenue accelerating to 48% growth, significantly beating 38% expectations.
Capex surge to $175-185 billion nearly doubles 2025 spending
The company announced plans to spend $55 billion more than consensus forecasted on AI infrastructure, causing an initial 7% after-hours stock drop before recovery.
Market digesting aggressive front-footed growth strategy
Analysts note that while heavy spending pressures near-term profits, these investments position Google for strong returns once the infrastructure build-out enters harvest mode after 2027.
💻 AI Anxiety Crushes Software Multiples 3 insights
Seat-based licensing models face existential threat
Investors are dumping software stocks over fears that AI automation will reduce workforce seats, directly threatening per-user revenue models at companies like Salesforce and ServiceNow.
AI agents displacing traditional software tools
New AI capabilities like Claude are replacing software functions entirely, forcing a 1-3 year period of uncertainty as the industry separates winners from losers.
Indiscriminate selling creates selective buying opportunities
The market's sell everything reaction to AI disruption may reward patient investors who identify companies that successfully adapt their competitive position with AI features.
💊 Weight Loss Drug Market Splits Dramatically 3 insights
Eli Lilly surges 10% on 43% revenue growth
Lilly raised 2026 guidance to $80 billion while rival Novo Nordisk warned of declining sales, sending the two stocks in opposite directions by nearly 30 percentage points.
Novo Nordisk struggles with pricing pressure and share loss
Novo's market share for injectables has slipped to 30-40% while facing Medicare price negotiations and competition from lower-priced alternatives.
Transition to oral therapies disrupts profitability
Novo's new oral pill costs roughly $150 monthly versus $300-500 for injectables, creating volume growth but severe revenue degradation that has erased all GLP-1 era stock gains.
Bottom Line
Despite market panic over massive AI spending and software disruption, patient investors with a 3-year horizon can find buying opportunities in companies making strategic infrastructure bets or adapting business models to AI, while avoiding those facing permanent obsolescence.
More from The Prof G Pod (Scott Galloway)
View all
Hong Kong's AI Crackdown, Lululemon’s Marketing Backlash, and World Cup Fever | China Decode
This episode examines escalating US-China tech tensions, with JP Morgan and Goldman Sachs restricting Anthropic AI access in Hong Kong while Washington pressures ASML over alleged advanced chip equipment shipments to China. The hosts also analyze Lululemon's marketing crisis in China, where a culturally ambiguous drum triggered nationalist backlash despite potentially Chinese origins.
Heather Cox Richardson: Is America Repeating the Gilded Age?
Historian Heather Cox Richardson and host Scott Galloway analyze the Trump administration's governance through the lens of the Gilded Age, focusing on institutional decay, performative politics over policy competence, and a potentially hollow Iran agreement that favors Tehran while exposing America's diplomatic weakness.
China Gets LOCKED OUT of SpaceX and America’s Biggest IPOs (ft. Ed Elson) | China Decode
The historic $86 billion SpaceX IPO marked a turning point in financial markets as Chinese investors were explicitly banned from participating, reflecting a broader bilateral decoupling where both Washington and Beijing are restricting cross-border capital flows to protect strategic tech interests and redirect investment toward domestic priorities.
The Future of Media Is Audio — ft. Axios’ Sara Fischer | Office Hours
Media correspondent Sara Fischer joins Scott Galloway to examine the collapse of trust at 60 Minutes under new ownership, the dangers of extreme media consolidation among politically connected billionaires, and how independent audio formats and reader-funded models are creating a sustainable alternative to traditional broadcast journalism.